SANTA BARBARA, Calif.--QAD Inc. (NASDAQ: QADI), a leading provider of enterprise software and services for global manufacturers, announced today that PROFARM PS, a fast growing pharmaceuticals distributor based in Poland, has extended its commitment to QAD by upgrading to QAD Enterprise Applications. QAD expects to complete the implementation rapidly and for the PROFARM system to go live by year-end 2010.
PROFARM, whose business is focused on growth from the vaccine market, needed a solution to address regulatory compliance issues of the pharmaceutical industry and provide validation of its IT systems to current good manufacturing practices (cGMP).
With a 13-year history with QAD, PROFARM elected to upgrade to QAD Enterprise Applications for its improved capabilities and performance. “We are committed to QAD because we are pleased with our long-term relationship,” explained Piotr Steczniewski, deputy CEO at PROFARM PS. “In addition, QAD understands how important transferring our data safely and efficiently is to our business.”
QAD has a strong foothold in the pharmaceutical market and understands the regulatory pressures and stringent requirements that its customers face, particularly the need to maintain secure and auditable systems.
”With QAD Enterprise Applications, PROFARM is equipped with the right tools to manage validation, electronic batch records and electronic signatures, comprehensive audit trails and other traceability issues, while reducing risk and cost-effectively managing its compliance initiatives,” said Jean-Claude Walravens, QAD senior vice president EMEA.
PROFARM was particularly impressed by QAD Enterprise Applications process maps, as they are designed specifically for the pharmaceutical market.
Overall, the implementation also will provide stock management, finance, accounting, and transport planning support, a function that, until recently, was prepared outside of the main system.
“We are very excited about this implementation. Our last IT system has been in service for many years and validation has proved demanding,” explained Steczniewski. “We believe with this upgrade, QAD will help us simplify the validation process and provide the overall functionality we need to grow.”
Join QAD on: Facebook, Twitter, LinkedIn, YouTube
About PROFARM PS
PROFARM PS Sp. z.o.o. is a leading distributor providing health products and supplies from pharmaceutical companies including Astra Zeneca, MSD, Abbott, Pfizer, Baxter and Ipsen International to hospitals and medical wholesalers. Established in 1989 and headquartered in Warsaw, Poland, PROFARM PS is one of the first private pharmaceutical companies in Poland.
QAD is a leading provider of enterprise applications for global manufacturing companies specializing in automotive, consumer products, electronics, food and beverage, industrial and life science products. QAD applications provide critical functionality for managing manufacturing resources and operations within and beyond the enterprise, enabling global manufacturers to collaborate with their customers, suppliers and partners to make and deliver the right product, at the right cost and at the right time. For more information about QAD, telephone +1 805-566-6000, or visit the QAD web site at www.qad.com.
"QAD" is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2009 ended January 31, 2009.
For additional information, contact:
+1 805 566 4513